ProQR Therapeutics N.V. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was EUR 1.21 million compared to EUR 0.93 million a year ago. Net loss was EUR 7.99 million compared to EUR 13.7 million a year ago. Basic loss per share from continuing operations was EUR 0.1 compared to EUR 0.19 a year ago. Diluted loss per share from continuing operations was EUR 0.1 compared to EUR 0.19 a year ago.
For the six months, sales was EUR 1.86 million compared to EUR 2.06 million a year ago. Net loss was EUR 16.93 million compared to EUR 27.81 million a year ago. Basic loss per share from continuing operations was EUR 0.21 compared to EUR 0.39 a year ago. Diluted loss per share from continuing operations was EUR 0.21 compared to EUR 0.39 a year ago.